ARCHWAY STUDY

...for wet AMD



Wet Macular Degeneration

Principal Investigator
Dr. Matthew Ohr

Phase III, multi-center, randomized, visual assessor-masked active-comparator study of the efficacy, saftey, and pharmacokinetics of the port delivery system with ranibisumab in patients with neovascular age-related macular degeneration

INCLUSION CRITERIA:

- At least 50 years of age with initial diagnosis of exudative nAMD within 9 months prior to the screening visit
- Previous treatment with at least three anti-VEGF intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit
- Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis, as evidenced at screening by overall decrease in nAMD disease activity detected on SD-OCT, and stable or improved BCVA
- BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent)

EXCLUSION CRITERIA:

- **Study Eye:**
  - History of any intervention treatment for AMD
  - Prior treatment with Visudyne®, radiation therapy, or transpupillary thermotherapy
  - Previous treatment with corticosteroid intravitreal injection
  - Aphakia or absence of the posterior capsule
  - Previous laser used for AMD treatment
  - Intraocular surgery (including cataract surgery) within 3 months preceding the randomization visit
- **Either Eye:**
  - Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit
  - Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the randomization visit, other than ranibizumab

CONTACT Havener Eye Institute Research Office • 614-293-5287 • Research@osumc.edu